Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Quanterix Q3 2026 Results: Net Loss of $21.6M, Loss Narrows

Quanterix Corp reported total revenues of $104.3 million for the nine months ended September 30, 2026, a 10% increase year-over-year, though it recorded a net loss of $88.1 million. The company's financial position was impacted by $46.9 million in impairment and restructuring costs and a significant decrease in marketable securities from $88.4 million to $41.5 million since the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue35.040.2
Gross profit13.515.9
Profit before tax-21.3-36.0
Net income-21.6-33.5
EPS (diluted, $ a share)$-0.46$-0.73

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-13.1%
Gross margin38.6%
Operating margin-64.3%
Source

10-Q filed with the SEC, NASDAQ: QTRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Quanterix Corp: key numbers

Share price
$2.84Close, Nov 16
Market cap
$135M
Shares outstanding
47.48MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Quanterix Corp

All →
8:08 AM ET 8-K
Financial Results

Quanterix Financial Results

Quanterix reported Q3 2026 revenue of $35.0 million, representing a 6.3% sequential increase despite market softness. The company ended the quarter with $80.7 million in cash and marketable securities while narrowing its net loss by 35.6% year-over-year to $21.6 million. Management highlighted new commercial leadership and expanded insurance coverage for its Alzheimer’s disease blood tests as key growth drivers.

Term
Q3 2026

“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses.”

Everett Cunningham, President & CEO

“We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth.”

Everett Cunningham, President & CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.